Study: Gene Edits in CRISPR Babies Could Boost Risk of Earlier Death

Xconomy

That’s according to a new study from University of California, Berkeley data scientists who analyzed the records of more than 400,000 people in the United Kingdom.

Study 71

Will New Study Cut Guesswork for Depression Medicine Prescriptions?

Xconomy

Genetic testing that helps guide more precise cancer treatment is making its way into standard practice in major U.S. medical centers. Could the same eventually be true for depression?

Study 63

ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More

Xconomy

The American Society of Clinical Oncology meeting in Chicago has wrapped up for another year. Last week, we featured two stories that you wouldn’t find at the ASCO frenzy: Immunotherapy’s lack of progress in treating breast cancer , and one woman’s risky bet of tens of millions of dollars from her personal fortune to speed drug development for the nastiest form of brain cancer.

Study 73

Viking Liver Drug Shows Promise for NASH, Shares Soar on Study Data

Xconomy

Viking Therapeutics released preliminary results from a Phase 2 study suggesting its experimental drug might impact some of the disease’s many dangerous effects on the liver.

Study 71

Blood Test Study Meets Goal, Validates Epic’s Prostate Cancer Target

Xconomy

In study results published Wednesday, the presence of the specific protein fragment that Epic (not to be confused with Verona, WI-based EHR software maker Epic Systems) tests for in circulating tumor cells predicted a shorter median length of survival for men whose disease has spread.

Study 90

Study: Reflexion Health Virtual Therapy System Reduces Rehab Costs

Xconomy

The study, which evaluated Reflexion’s system for patients after total knee replacement surgery, was conducted in conjunction with the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine.

Study 82

How an Ohio Kids’ Hospital Quietly Became Ground Zero for Gene Therapy

Xconomy

If a once-modest regional hospital and its new biotech allies have their way, the capital of Ohio could one day rival America’s other biomedical hubs. Our goal is to make Columbus the center of the universe for gene therapy,” says Doug Ingram, CEO of Sarepta Therapeutics.

Economic Study Ranks San Diego Near Top in Genomics Innovation

Xconomy

An economic impact study of San Diego’s emerging genomics industry counted 115 genomics-related companies operating in the region that directly employ over 10,000 people, and drive about $5.6 After previewing a glimpse of the study’s findings last month , Brady provided.

Bio Roundup: Zolgensma Watch, Brain Cancer Blues, Peloton Payout & More

Xconomy

Merck Nasdaq NEA Nektar Therapeutics New Enterprise Associates Novartis Nuevolution NYSE opioid painkiller PatientsLikeMe pembrolizumab pricine Pricing regulation Rene Russo RNA Royalty Scott Gottlieb SCOTUS SMA Spinal Muscular Atrophy Study subsidiary T-cell therapy Tocagen US Supreme Court value Vas Narasimhan VC Venture Capital Voyager Therapeutics watchdog Zolgensma

Study 61

If Budget Holds, NIH Precision Study Could Be Flush As Volunteers Arrive

Xconomy

That included the Precision Medicine Initiative, an ambitious long-term study with the goal of recruiting 1 million Americans to volunteer health data. Until this week, many U.S. government science agencies and programs seemed destined for a big haircut, plus the loss of a limb or two.

Study 52

Study Stakes San Diego’s Claim in Genomics: $292M in 2016 VC Deals

Xconomy

Preliminary findings from an economic impact study show that genomics is emerging as a distinct innovation cluster in San Diego. The San Diego Regional Economic Development Corp.

As U.S. Looks to Launch Precision Health Study, Google’s Role Emerges

Xconomy

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. To be clear, health data that citizens contribute to the study will be open for research under the purview of the government—not held privately by Google or the other two dozen entities that are building and running the four cornerstones of the PMI.

Study 61

Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend Lives

Xconomy

Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they?

Guide 73

New Study: DNA Tests For Healthy People Have “Uncertain Value”

Xconomy

A new study published Monday in the Annals of Internal Medicine questions the practicality of making DNA tests standard for people who don’t have a cancer diagnosis or aren’t trying to identify a mysterious disease. The study is limited by its small scope, but it is the first with some rigor to examine outcomes. Genome sequencing is becoming more common for people diagnosed with cancer. Should it become part of a healthy person’s checkup, too?

Study 46

BLOGGER ALERT: How to Start a Blog and Make Money Blogging

Tech Zulu Event

In this article you’ll discover how to start a blog that makes money. There are four types of blogs; written blogs, video blogs, photo blogs and a combination of these. We’ll primarily be discussing written blogs. How to make money with a written blog.

For Sickle Cell, a Complex Disease, New Drugs Could Bring Complex Costs

Xconomy

Cassandra Trimnell has sickle cell disease. She also loves to travel. For her 30th birthday last year, she and her husband planned a trip to Indonesia, and she figured she would be fine.

Study 83

“Unseen Is Unsold:” VR & Analytics Study What and Why Shoppers Buy

Xconomy

Humans are great about saying a lot of things. We’re not that good about actually following through. See: New Year’s diet resolutions or election polls. That tendency affects retailers as well. Big stores and brands spend millions in market research to figure out what shoppers want and then model production and creative teams to create those items. What people say and what people do is different,” says Anne Stephenson, a partner with Explorer Research, which works with retailers and brands. “So,

Study 45

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

Xconomy

It’s the start of a plan whose seeds were planted more than two years ago, when former President Barack Obama proposed a study to glean insights about health and disease by tracking a large. An ambitious plan to recruit 1 million U.S.

Study 78

Study: Users Not Willing To Pay To Use Twitter, Other Online Services

socalTECH

A study released Friday by the Center for the Digital Future, at the USC Annenberg School of Communications, finds that zero percent of Twitter users polled in the study would pay for Twitter. According to the study, it found that 49 percent of Internet users have used micro-blogging services like Twitter, but found that there was zero percent of users polled were willing to pay for such a service directly.

Study 147

Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

Xconomy

[ Editor’s note: Ben Fidler and Sarah de Crescenzo coauthored this report.] It is here, and then it is gone. But by the time everyone staggers to the airport or back home to sleep in their own beds, the annual few days of the J.P. Morgan Healthcare Conference and everything that mushrooms around it seem just as long as the holiday break—a distant memory!—that —that came just before. In 2020 (yes, that’s really a year), San Francisco might have a new mayor.

For More Lung Cancer Patients, the Promise of No Chemo Looms Larger

Xconomy

[ Editor’s note: Ben Fidler co-authored this report.] A decade from now, it’s possible that immunotherapy will have made a big dent in lung cancer, which is by far the deadliest type of the disease.

Study 68

Recruitment Goal In Obama Precision Med Study: 1M in 3 or 4 Years

Xconomy

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

PMI 58

Cirius Therapeutics Raises $40M to Expand Ongoing Liver Study

Xconomy

A $40 million transfusion led by Frazier Healthcare Partners and Denmark’s Novo A/S is bringing fresh life to a Michigan biotech working to advance a new experimental drug for treating a type of non-alcoholic fatty liver disease.

Study 56

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Xconomy

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million. And like Juno, Allogene is working with a live immune-cell treatment called CAR-T, but it is harvesting cells from anonymous donors instead of from the same patients slated to receive the therapy, which is Juno’s method.

Doc 53

Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More

Xconomy

America continues to suffer from healthcare headaches. Our convoluted private-public insurance system was under scrutiny this week from Democrats, holding a “Medicare for All” hearing in the House , and from Republicans, as several GOP-led states and the Trump administration asked a federal court to sweep away Obamacare. Several companies also want to reduce headaches.

Often Advocates Of Faster FDA, Patient Groups Wary Of Trump Deregulation

Xconomy

In the biomedical world, perhaps the biggest question looming over President Donald Trump’s upcoming pick for Food and Drug Administration commissioner is how drastically that person will help roll back FDA regulations. Trump said at last week’s meeting in Washington D.C.,

Study 77

Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

Xconomy

Before you fly off, or drive, or simply unplug, check out our preview of what could be next year’s top clinical studies; the tumult in big pharma’s on again-off again relationship with consumer healthcare; big names on the move in the nation’s capital; and a flurry of year-end deals. It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.

BIO Has Big Diversity Goals. Does It Have the Means to Reach Them?

Xconomy

Whether from embarrassing parties or sobering surveys, the biotech gender gap problem has made plenty of headlines the past couple years. The industry’s largest trade group, the Biotechnology Industry Organization (BIO), is trying to encourage its more than 1,000 member companies to do better.

Bio Roundup: Depression Drug Dashed, Peek at ASH, CRISPR Worry & More

Xconomy

Studies of CRISPR-Cas9 to treat human disease are about to start, too. This week, we reported on a new study that raises exactly that question. The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells. But will our immune systems, already on alert for common infections by the bacteria that produce Cas9 proteins, reject medicines that use the gene-snipping scissors?

Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More

Xconomy

One group of people in dire need of medical relief got good news this week. The first drug for postpartum depression was approved. With its complicated logistics, side effects, and potential high cost, it won’t be for everyone who experiences the condition— 1 of every 9 U.S. women giving birth. But at least it’s an option.

News 47

Possible Cures. Mystery Deaths. Daunting Costs. Can CAR-T Be Tamed?

Xconomy

It’s a struggle that comic-book fans know well. Ordinary people, bestowed with super powers from a spider bite or gamma rays, struggle to harness their own abilities. T cells, key soldiers of the immune system, are wrestling with new-found super powers, too.

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

In a week of big personnel moves, none was more surprising than Editas Medicine CEO Katrine Bosley’s departure. After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday. Investors were not happy.

Ionis Touts Phase 3 Win, But Safety Worries Cloud Nerve Drug Study

Xconomy

Two RNA-based drugs for the same disease, a rare, crippling nerve condition called familial amyloid polyneuropathy (FAP) with no available treatments in the U.S., could soon be under an FDA review at the same time.

Study 54

Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study

Xconomy

National blog main New York New York blog main New York top stories San Diego blog main San Francisco blog main Acadia Pharmaceuticals Acorda Therapeutics Adamas Pharmaceuticals amantadine Biotie Therapies clinical trials Drugs FDA Gocovri Inbrija Leerink Partners Life Sciences Parkinson's Disease Paul Matteis Ron Cohen Scopia Capital Management tozadenant

Study 43

BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage

Xconomy

Take the results of a Phase 3 study just reported today at the American Society of Hematology’s (ASH) yearly meeting in San Diego.

Study 83